Saturday December 14, 2019 13:09

Heathcare Press Release : 23 Sep 2019

New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Heathcare—23 Sep 19

BAVENCIO(R) (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX(R) (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, M6620 (ATR inhibitor): 1547, Combinations: 4062; 4934. - New subgroup analyses for first-line

CHMP Adopts Positive Opinion for BAVENCIO(R) (avelumab) Plus Axitinib for First-Line Treatment of Heathcare—23 Sep 19

- Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib1 - Decision by the European Commission anticipated in fourth quarter of 2019 Merck and